Logo-npj
Submitted: 30 May 2022
Accepted: 07 Jul 2022
ePublished: 08 Jul 2022
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Nephropharmacol. 2022;11(2): e10485.
doi: 10.34172/npj.2022.10485
  Abstract View: 1720
  PDF Download: 219

Letter to Editor

Hope and fear; Paxlovid for COVID-19 treatment: A Letter to the Editor

Alireza Pouramini 1 ORCID logo, Maryam Khosravian 2 ORCID logo, Fatemeh Kafi 1 ORCID logo, Sina Bakhshaei 3,4 ORCID logo, Hamid Reza Jahantigh 5 ORCID logo, Payam Peymani 6 ORCID logo, Neda Kianpour 7 ORCID logo, Majid Foroutan 8* ORCID logo

1 Nickan Research Institute, Isfahan, Iran
2 Department of Internal Medicine I, Martin Luther University, Halle, Germany
3 Temecula Valley Hospital, Temecula, California, USA
4 UHS SoCal MEC (Universal Health Service Southern California Medical Education Consortium), Internal Medicine Residency Program, Temecula, California, USA
5 Animal Health and Zoonosis PhD Course, Department of Veterinary Medicine, University of Bari, Bari, Italy
6 College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada
7 Department of Biotechnology, Inland Norway University of Applied Science, Hamar, Hedmark, Norway
8 Department of Internal Medicine, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran
*Corresponding Author: Corresponding author: Majid Foroutan, Email: dr_forotan@yahoo.com, , Email: dr_forotan@semums.ac.ir

Implication for health policy/practice/research/medical education:

Paxlovid is an effective oral treatment for COVID-19 patients that reduces mortality and can be administered in an outpatient setting, but it cannot substitute COVID-19 immunizations.

Please cite this paper as: Pouramini A, Khosravian M, Kafi F, Bakhshaei S, Jahantigh HR, Kianpour N. Foroutan M. Hope and fear; Paxlovid for COVID-19 treatment: A Letter to the Editor. J Nephropharmacol. 2022;11(2):e10485. DOI: 10.34172/npj.2022.10485.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 1721

Your browser does not support the canvas element.


PDF Download: 219

Your browser does not support the canvas element.